ExpreS2ion Biotechnologies - Presentation of Q1 2025
You can already now sign up for the event and send in your questions. You don’t have to participate live to submit your questions for the event.
ExpreS2ion Biotechnologies is expected to release its Q1 2025 results on 15 May 2025. Later on the same day at 10:30, the management will present the results and the achievements in an online live presentation. The presentation will be followed by a Q&A session.
Besides the financial results for the first quarter, focus could be on the capital situation and runway through 2025, as well as update on the timelines and development in the pipeline, especially seen in the light of the update the company released late March regarding the phase 1 trial for ExpreS2ion’s HER2 cancer vaccine candidate, ES2B-C001. Despite expectations of dosing the first patient during Q1 2025, no patients have been dosed yet, but with the company stating that the delay has nothing to do with any safety or scientific concerns. Furthermore, on the back of a strategic review, ExpreS2ion also decided not to pursue further development of its CMV vaccine candidate, a development conducted in collaboration with Evaxion Biotech.
ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its ExpreS2 production platform with AdaptVac's VLP technology.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 11.57 9 April 2025.
